- Home
- MRCC vs ALEC Comparison
MRCC vs ALEC Comparison
Compare MRCC & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | ALEC |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.8M | 262.7M |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MRCC | ALEC |
|---|---|---|
| Price | $4.79 | $2.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | 142.0K | ★ 743.0K |
| Earning Date | 06-08-2026 | 05-25-2026 |
| Dividend Yield | ★ 7.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $45.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.11 | $0.87 |
| 52 Week High | $7.92 | $3.40 |
Technical Indicators
Market Signals| Indicator | MRCC | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 55.09 |
| Support Level | $4.11 | $1.22 |
| Resistance Level | $6.91 | $2.55 |
| Average True Range (ATR) | 0.32 | 0.19 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 33.73 | 50.00 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.